Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 10/20 | 0.41 |
| ▸ | TACR2 | P21452 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | MC5R | P33032 | 1/20 | 0.37 |
| ▸ | MC3R | P41968 | 1/20 | 0.37 |
| ▸ | MC1R | Q01726 | 1/20 | 0.37 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.37 |
| ▸ | OXTR | P30559 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5447100 | 1.00 | MC4R (0.41) | MC4RTACR2TACR1MC5RMC3R | |
| SCHEMBL5447104 | 1.00 | MC4R (0.41) | MC4RTACR2TACR1MC5RMC3R | |
| SCHEMBL5453829 | 0.93 | TACR2 (0.41) | MC4RTACR2TACR1MC5RMC3R | |
| SCHEMBL5443890 | 0.93 | TACR2 (0.41) | MC4RTACR2TACR1MC5RMC3R | |
| SCHEMBL5443887 | 0.93 | TACR2 (0.41) | MC4RTACR2TACR1MC5RMC3R | |
| SCHEMBL5214537 | 0.90 | MC4R (0.43) | MC4RAVPR1A | |
| SCHEMBL5458234 | 0.90 | MC4R (0.43) | MC4RAVPR1A | |
| SCHEMBL5214527 | 0.90 | MC4R (0.43) | MC4RAVPR1A | |
| SCHEMBL5449594 | 0.88 | CYP51A1 (0.44) | MC4RMC5RMC3RMC1R | |
| SCHEMBL5453848 | 0.88 | MC4R (0.45) | MC4RMC5RMC3RMC1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | claimed |
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191364-A1 | AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MC4R, MC5R, TAAR5 | MC4R 1/4885TACR2 216/4885TACR1 147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.